secwatch.observer — SEC 8-K summary
======================================

Issuer:     Annovis Bio, Inc. (ANVS)
CIK:        0001477845
Form:       8-K
Filed at:   2026-02-12T23:59:59+00:00
Accession:  0001104659-26-013948
Event type: other_material
Sentiment:  positive
Materiality: 0.65
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Annovis Bio receives DSMB approval to continue Phase 3 Alzheimer's trial of buntanetap
--------------------------------------------------------------------------------

- DSMB issued positive recommendation on buntanetap safety at 6 months; trial continues without modification.
- Phase 3 AD trial is 40% complete; first symptomatic efficacy readout expected in early 2027.
- FDA indicated it may accept combined safety data from Alzheimer's and Parkinson's studies in future NDA submission.
- 6-month safety data in Alzheimer's patients consistent with those observed in Parkinson's patients.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1477845/000110465926013948/0001104659-26-013948-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1477845/000110465926013948/tm266101d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-26-013948

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer